Driver mutations in the EGFR, BRAF, and KRAS genes represent a combined ~60% of all genomic variants driving oncogenesis of many solid tumor diseases, especially lung cancer. SeraCare is expanding its Seraseq liquid biopsy portfolio with the addition of low-plex (single-gene) reference materials for clinically-validated biomarkers as ground-truth standards for molecular testing of circulating tumor DNA patient samples by PCR or NGS technologies. These products are designed for validation and standardization of clinical biomarkers in CLIA/CAP-accredited laboratory developed tests (LDTs).
The Seraseq ctDNA Reference Material WT (0%) product is the wild-type with an allele frequency of 0%.
Size distribution similar to native cfDNA
Offered in a full-process plasma-like material capable of assessing the entire workflow from extraction through analysis
Mutation precisely quantitated with digital PCR
Single well-characterized GM24385 human genomic DNA as background wild-type material
Manufactured in GMP-compliant and ISO 13485-certified facilities